Perbedaan Kadar Pentraxin 3 pada Pasien Hepatitis B Kronik dengan Sirosis dan Tanpa Sirosis

Abstract

Background: Hepatitis B virus (VHB) is the world's leading infectious disease that is still a public health problem and can develop into cirrhosis of the liver. The inflammatory response is one of the mechanisms that play a role in pathogenesis of chronic hepatitis B and liver cirrhosis. Many studies have used elevated levels of Pentraxin 3 as a predictor of the severity in Chronic Hepatitis B patients with or without liver cirrhosis. Method: The design of this study is cross-sectional consecutive sampling. The study population is chronic hepatitis patients with and without liver cirrhosis admitted to Gastroenterohepathology department of RSUP H. Adam Malik Medan. Result: The demographic characteristic of the study is dominated by male in the two study groups. This study found a significant difference between the mean value of Pentraxin 3 in Hepatitis B chronic patient with liver cirrhosis group compared to the group without liver cirrhosis (p<0,001). Conclusion: There is a significant difference between the level of Pentraxin 3 in Hepatitis B Chronic patient with liver cirrhosis compared to Hepatitis B Chronic patient without liver cirrhosis group (p<0,001) in which the level of Pentraxin 3 in Hepatitis B Chronic with liver cirrhosis group is higher compared to group without liver cirrhosis. Therefore the level of Pentraxin 3 can be used as an alternative marker to assess the progression of liver cirrhosis in Hepatitis B Chronic patients.